BAT1006 is a monoclonal antibody targeting the extracellular domain II of HER2, with enhanced antibody-dependent cell-mediated cytotoxicity (ADCC). It is utilized for research in HER2-positive locally advanced/metastatic solid tumors. Compared to pertuzumab, BAT1006 exhibits roughly 5 times increased ADCC effect and demonstrates potent antitumor activity in HER2-positive Calu-3 xenograft mouse models.